Related Experiment Videos
Universal serologic reaction in neoplastic disease
American Journal of Clinical Pathology
|January 1, 1952
Summary
No abstract available in PubMed .
Keywords:
NEOPLASMS/blood inRelated Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1986
An evaluation of reports of dioxin exposure and soft tissue sarcoma pathology among chemical workers in the United States.
Scandinavian journal of work, environment & health·1984
Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54.
American journal of clinical pathology·1977
Additive diagnostic value of liquid‑based preparation and conventional smears in Bethesda I thyroid nodules.
American journal of clinical pathology·2026
American Society for Clinical Pathology (ASCP) and ASCP Board of Certification medical and public health laboratory education financing study.
American journal of clinical pathology·2026
The essentials-measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions.
American journal of clinical pathology·2026
Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.
American journal of clinical pathology·2026
Communication patterns among surgical pathologists: a retrospective review of ideal strategies in a tertiary care setting.
American journal of clinical pathology·2026
Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.
American journal of clinical pathology·2026
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026